ScreenerHero

CUECue Biopharma, Inc.

NAS · US · Healthcare · Biotechnology · cuebiopharma.com
23.98USD-8.75%Mkt Cap: 174.20M $P/E: —

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap174.20M $
Enterprise Value124.36M $
Revenue (TTM)32.73M $
Gross Profit-862.00K $
Net Income (TTM)-26.60M $
Revenue/Share8.750 USD
Last Price23.98 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS22978P1066
Valuation
P/E (Trailing)—
P/E (Forward)-51.27
PEG—
EV/EBITDA-6.85
EV/Revenue3.80
P/S5.46
P/B3.00
EPS (TTM)-27.27
EPS (Forward)-0.48
52W Range
4.98047% of range45.50
52W High45.50 USD
52W Low4.980 USD
Profitability
Gross Margin-2.63%
Oper. Margin-94.32%
EBITDA Margin-55.49%
Profit Margin-96.85%
ROE-100.64%
ROA-63.02%
Growth
Revenue Growth1250.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.69M $
CapEx (TTM)177.00K $
FCF Margin-45.51%
FCF Yield-8.55%
Net Debt-14.00M $
Net Debt/EBITDA0.77
Balance Sheet
Debt/Equity0.16
Current Ratio3.57
Quick Ratio3.34
Book Value/Sh8.207 USD
Cash/Share4.311 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateApr 24, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)115.00 USD
Upside (mean)+379.6%
Target Range115.00 USD – 115.00 USD
# Analysts1
Ownership
Shares Out.7.26M
Float3.66M
Insiders19.67%
Institutions40.40%
Short Interest
Short Ratio2.1d
Short % Float9.08%
Short % Out.8.33%
Shares Short349.88K
Short (prev mo.)298.08K
Technical
SMA 5029.24 (-18.0%)
SMA 20018.46 (+29.9%)
Beta2.47
S&P 52W Chg18.16%
Avg Vol (30d)193.53K
Avg Vol (10d)232.53K
Technical Indicators
RSI (14)40.3
MACD-0.5910
MACD Signal-0.2501
MACD Hist.-0.3409
BB Upper34.35 USD
BB Middle28.77 USD
BB Lower23.20 USD
BB Width38.73%
ATR (14)3.691 USD
Vol Ratio (20d)0.86x